NO981822L - Use of the GAX protein for the treatment of cancer - Google Patents

Use of the GAX protein for the treatment of cancer

Info

Publication number
NO981822L
NO981822L NO981822A NO981822A NO981822L NO 981822 L NO981822 L NO 981822L NO 981822 A NO981822 A NO 981822A NO 981822 A NO981822 A NO 981822A NO 981822 L NO981822 L NO 981822L
Authority
NO
Norway
Prior art keywords
cancer
treatment
gax protein
gax
protein
Prior art date
Application number
NO981822A
Other languages
Norwegian (no)
Other versions
NO981822D0 (en
Inventor
Aude Leroux
Didier Branellec
Patrice Denefle
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO981822D0 publication Critical patent/NO981822D0/en
Publication of NO981822L publication Critical patent/NO981822L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO981822A 1995-10-31 1998-04-23 Use of the GAX protein for the treatment of cancer NO981822L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9512871A FR2740344B1 (en) 1995-10-31 1995-10-31 APPLICATION OF PROTEIN GAX TO THE TREATMENT OF CANCERS
PCT/FR1996/001690 WO1997016459A1 (en) 1995-10-31 1996-10-28 Use of protein gax for treating cancer

Publications (2)

Publication Number Publication Date
NO981822D0 NO981822D0 (en) 1998-04-23
NO981822L true NO981822L (en) 1998-04-23

Family

ID=9484112

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981822A NO981822L (en) 1995-10-31 1998-04-23 Use of the GAX protein for the treatment of cancer

Country Status (13)

Country Link
EP (1) EP0858466A1 (en)
JP (1) JPH11514881A (en)
KR (1) KR19990067174A (en)
AU (1) AU730324B2 (en)
BR (1) BR9611206A (en)
CA (1) CA2233250A1 (en)
CZ (1) CZ131598A3 (en)
FR (1) FR2740344B1 (en)
HU (1) HUP9900011A3 (en)
NO (1) NO981822L (en)
SK (1) SK56198A3 (en)
WO (1) WO1997016459A1 (en)
ZA (1) ZA969147B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754822B1 (en) * 1996-10-18 1998-11-27 Rhone Poulenc Rorer Sa POLYPEPTIDES COMPRISING PROTEIN GAS DOMAINS, INVOLVED IN TRANSCRIPTION REPRESSION AND / OR INTERACTING WITH OTHER PROTEINS, CORRESPONDING NUCLEIC ACIDS AND USES THEREOF
AU2001289652A1 (en) * 2000-06-28 2002-01-08 Aventis Pharma S.A. Compositions and methods for regulating the cell cycle using a ki gene or polypeptide
US20100285056A1 (en) 2008-01-09 2010-11-11 Konkuk University Industrial Cooperation Corp. Baculovirus-Based Vaccines
WO2011055888A1 (en) 2009-11-06 2011-05-12 Chung-Ang University Industry-Academy Cooperation Foundtion Nanoparticle-based gene delivery systems
KR101232123B1 (en) 2010-10-08 2013-02-12 연세대학교 산학협력단 Gene Delivery Systems Exhibiting Enhanced Tumor-Specific Expression with Recombinant Expression Control Sequence
KR101427200B1 (en) 2011-11-24 2014-08-07 주식회사 바이로메드 A Novel Cell Line for Producing Adenovirus and Its Uses
KR101429696B1 (en) 2012-11-21 2014-08-13 국립암센터 Recombinant adenovirus with enhanced safety and anti-cancer activity and use thereof
WO2017065497A1 (en) 2015-10-12 2017-04-20 한양대학교 산학협력단 Adenovirus complex for gene transfer and gene therapy
KR102167934B1 (en) 2017-12-13 2020-10-20 진메디신 주식회사 Recombinant adenovirus and mesenchymal stem cell comprising thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705361B1 (en) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Viral vectors and use in gene therapy.
US5856121A (en) * 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
FR2732357B1 (en) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa VIRAL VECTORS AND USE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS, ESPECIALLY RESTENOSIS

Also Published As

Publication number Publication date
NO981822D0 (en) 1998-04-23
JPH11514881A (en) 1999-12-21
FR2740344A1 (en) 1997-04-30
AU7498296A (en) 1997-05-22
AU730324B2 (en) 2001-03-01
CZ131598A3 (en) 1998-08-12
SK56198A3 (en) 1998-11-04
WO1997016459A1 (en) 1997-05-09
BR9611206A (en) 1999-03-30
HUP9900011A2 (en) 1999-04-28
CA2233250A1 (en) 1997-05-09
EP0858466A1 (en) 1998-08-19
ZA969147B (en) 1997-05-27
HUP9900011A3 (en) 1999-11-29
KR19990067174A (en) 1999-08-16
FR2740344B1 (en) 1997-11-21

Similar Documents

Publication Publication Date Title
FI964874A (en) Treatment of vegetables
NO971015D0 (en) Compounds and Methods for the Treatment of Cancer
NO952573D0 (en) Preparations for the treatment of diabetic complications
NO976063D0 (en) Procedure for the treatment of diabetes
NO991381L (en) Combination therapy for the treatment of psychoses
LV11615A (en) Amid with medical treatment
NO991955L (en) Process for the treatment of hydrocarbons
NO982172D0 (en) Use of epinastine for the treatment of pain
FI971568A (en) Procedure for the treatment of resistant tumors
FI956339A (en) Treatment of absence of hypothalamic menstruation
ID18679A (en) USE OF FURTHER THERAPY
DE19681419T1 (en) Treatment system
NO991459D0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
IS4528A (en) Bicyclic derivatives of isothio urea useful therapeutic treatment
NO981822D0 (en) Use of the GAX protein for the treatment of cancer
EE03437B1 (en) Benzenamides for the treatment of neurodegenerative diseases
NO982582D0 (en) Procedure for treating pain
NO982562D0 (en) Composition for the treatment of pain
DE59607418D1 (en) HAIR TREATMENT
NO986053D0 (en) Anticonvulsant derivatives for the treatment of psoriasis
NO20000274D0 (en) Treatment of fluids
NO962812D0 (en) Procedure for the treatment of pneumonia
ID24439A (en) USE OF TIAZOLIDINDION FOR HYPERGLICEMIA TREATMENT
NO952526D0 (en) Methods for the treatment of rheumatism
KR970020845U (en) Supplementary tape for the treatment of musculoskeletal diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application